Initiate the Phase 2 study for achondroplasia
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Nov 2024
- Due
- 31 Mar 2025
- Delivered
- August 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We look forward to initiating the Phase 2 study for ACH in the first quarter of 2025”
What we found
Evidence strength A What the grades mean
The company committed to initiating the Phase 2 study in Q1 2025, but the first child was not dosed until August 2025, missing the original deadline.
-
A Tyra Biosciences, Inc. 10-K filed 2026-03-02
“In August 2025, we announced that the first child was dosed in BEACH301, a global, Phase 2, multi-center, open-label clinical trial of oral dabogratinib for children ages 3 to 10 with ACH” ✓ confirmed on the page
Market reaction: the shares moved +6.0% against the S&P 500 over the three sessions around the disclosure (27 Feb 2026 to 4 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 study for achondroplasia
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tyra Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-TYRA-002079 · Corrections policy